The substantial presence of specialty pharmaceuticals companies in the CDER approval list ... potential diabetes drug, the long-acting glucagon-like peptide 1 (GLP1) analogue liraglutide, was ...
9don MSN
Stock Advisor provides investors with an easy-to-follow blueprint for success, including guidance on building a portfolio, regular updates from analysts, and two new stock picks each month. The Stock ...
As the Cooper administration transitions to the Stein administration, leadership changes are happening across state cabinets ...
Asit Sharma: I think the weight loss drug, GLP1 class drugs are catching a breath ... That's one more book that I have to put on a long list of recommendations from yourself and Mary.
Zacks.com on MSN8d
Abbott Stock Trades at a Discounted P/B Value: To Buy or Not to Buy?Abbott Laboratories ABT shares are trading at a discount to the Zacks Medical Products industry. Its trailing 12-month price-to-book value of 4.91X is significantly lower than the industry average of ...
Zacks.com on MSN21d
Is Abbott Stock Worth Buying at a Discounted P/S Valuation?Recently, the company completed additional agreements to get access to biosimilar versions of market-leading autoimmune ...
During JPM week, virtual care companies strut their plans to make GLP-1 drugs work harder, cost less
Digital health companies' plans focused on managing the impact of GLP-1 drugs, which have placed enormous pressure on health ...
Intuitively, it would seem that GLP-1 use for obesity would reduce overall medical costs despite the increase in drug ...
A study has found no evidence that glucagon-like peptide 1 receptor agonist (GLP1-RA) use is associated with an increased risk of thyroid cancer. The study is published in the peer-reviewed ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback